4 Results for "

Familial Adenomatous Polyposis

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "Familial Adenomatous Polyposis" in MCE Product Catalog:

4
4 Cited Publications
Cat. No.: HY-100685
CAS No.: 150045-18-4
Purity:  99.45%
Synonyms: BE-34776
Target:  

HuR Apoptosis COX

Research Areas:  

Neurological Disease Cancer

MS-444 (BE-34776) is a HuR (ELAVL1) inhibitor that blocks the cytoplasmic translocation of HuR and inhibits its dimerization. MS-444 reduces cytoplasmic HuR levels by preventing the binding of HuR to ARE-mRNA, without altering the total expression of HuR. MS-444 induces apoptosis, inhibits cell growth, angiogenesis and invasion, and also regulates immune function and microbiota. MS-444 effectively alters the number, size and invasiveness of tumors in various cancer models. MS-444 is tolerable to intraperitoneal injection in vivo and can be applied to research related to colorectal cancer, familial adenomatous polyposis, colitis-associated cancer and glioblastoma .
loading...
    loading...
Cat. No.: HY-109182
CAS No.: 2230282-02-5
Purity:  99.95%
Synonyms: JNJ-64251330
Target:  

JAK STAT

Research Areas:  

Inflammation/Immunology

Lorpucitinib (JNJ-64251330) is an orally active pan-JAK inhibitor with good enteric selectivity and safety. Lorpucitinib can inhibit the JAK/STAT pathway and reduce the levels of inflammatory biomarkers in serum. Lorpucitinib can be used in the research of familial adenomatous polyposis and gastrointestinal inflammatory diseases .
loading...
    loading...
Cat. No.: HY-118139
CAS No.: 170569-87-6
Purity:  99.42%
Target:  

COX

Research Areas:  

Inflammation/Immunology

Desmethyl Celecoxib (compound 3b) is a selective cyclooxygenase-2 (COX-2) inhibitor (IC50=32 nM) with anti-inflammatory activities. Desmethyl Celecoxib is an analog of Celecoxib and with the optimal yield of 75% .
loading...
    loading...
Cat. No.: HY-178028
CAS No.: 3113303-04-8
Research Areas:  

Cancer

PRMT5-IN-53 is a gut-restricted and orally active PRMT5 inhibitor with pIC50s of ≥ 9.7 against hPRMT5 and mPRMT5. PRMT5-IN-53 binds to the PRMT5:MEP50 complex with a KD of 11.3 pM. PRMT5-IN-53 effectively inhibits PRMT5 locally in the intestines of mice, significantly reducing the number and area of polyps, while avoiding systemic hematological toxicity (such as anemia, neutropenia). PRMT5-IN-53 can be used for the study of colorectal cancer especially for familial adenomatous polyposis (FAP) .
loading...
    loading...